Trial in progress: Phase 1b/3 study of bemarituzumab+mFOLFOX6+nivolumab versus mFOLFOX6+nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)-MedSci.cn

Trial in progress: Phase 1b/3 study of bemarituzumab+mFOLFOX6+nivolumab versus mFOLFOX6+nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)

Wainberg, ZA; Van Cutsem, E; Moehler, MH; Kang, YK; Yen, P; Finger, E; Keegan, A; Shitara, K

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务